House dust mite sublingual immunotherapy: A double-blind, placebo-controlled study in elderly patients with allergic rhinitis

Clinical and Experimental Allergy

Volumn 43, Issue 2, 2013, Pages 242-248

  Bozek, A ^a   Ignasiak, B ^b   Filipowska, B ^a   Jarzab, J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Allergy Outpatient Clinic   (Poland)

Author keywords

Allergic rhinitis; Elderly; IgE; Immunotherapy

Indexed keywords

PLACEBO; STALLERGEN;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG USE; FEMALE; HOT FLUSH; HOUSE DUST ALLERGY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL PRURITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUBLINGUAL IMMUNOTHERAPY;

ADMINISTRATION, SUBLINGUAL; AGED; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL PROVOCATION TESTS; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 84872506918     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12039     Document Type: Article

References (26)

1. Wolkewitz M, Rothenbacher D, Low M et al. Lifetime prevalence of self-reported atopic diseases in a population-based sample of elderly subjects: results of the ESTHER study. Br J Dermatol 2007; 156:693-7.
2. Becerril Angeles M, Vazquez Merino CL, Angeles Garay U et al. Prevalence of allergic diseases in the elderly. Rev Alerg Mex 2008; 55:85-91.
3. Bush RK, Swenson C, Fahlberg B et al. Houste dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 2011; 127:974-81.
4. Mortemousque B, Bertel F, De Casamayor J et al. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo controlled study. Clin Exp Allergy 2003; 33:464-9.
5. Lue KH, Lin YH, Sun HL et al. Clinical and immunological effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-15.
6. Wang H, Lin X, Hao C et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006; 61:191-7.
7. Guez S. House-dust-mite sublingual-swallow immunotherapy in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000; 55:369-75.
8. Yukselen A, Kendrili SG, Yilmaz M et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double blind, double-dummy study. Int Arch Allergy Immunol 2012; 157:288-98.
9. Compalati E, Passalacqua G, Bonini M et al. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of GA2LEN meta-analysis. Allergy 2009; 64:1570-9.
10. Varney VA, Tabbah K, Mavroleon G et al. Usefulness of specific immunotherapy in patients with severe perennial rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33:1076-82.
11. Bousquet J, Khaltaev N, Crus AA et al. Allergic rhinitis and its impact on asthma (ARIA)2008. Allergy 2008; 63:8-160.
12. Heinzerling LM, Burbach GJ, Edenharter G et al. GA2LEN skin test study I: GA2LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy 2009; 64:1498-506.
13. Bachert C, Berdel D, Enzmann H. Richtlinien fur die Durchfuhrung von nasalen Provocationtests mit Allergen bei Erkrankungen der oberen Luftwege. Allergologie 1990; 13:53-5.
14. Dordal MT, Lluch-Bernal M, Sanchez MC et al. Allergen-specific nasal provocation testing: review by the Rhinoconjunctivitis Committee of the Spanish Society of Allergy and Clinical Immunology. J Investig Allergol Clin Immunol 2011; 21:1-12.
15. Bousquet PJ, Combescure C, Neukirch F et al. Original article: visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007; 62:367-72.
16. Raherison C, Nejjari C, Marty ML et al. IgE level and Phadiatop in an elderly population from the PAQUID cohort: relationship to respiratory symptoms and smoking. Allergy 2004; 59:940-5.
17. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53:461-72.
18. Radulovic S, Calderon MA, Wilson D et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 8:CD002893.
19. Compalati E, Passalacqua G, Bonini M et al. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009; 64:1570-9.
20. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol 2004; 135:332-5.
21. Armentia A, Fernandez A, Tapias JA et al. Immunotherapy with allergic extracts in geriatric patients: evaluation of effectiveness and safety. Allergol Immunopathol 1995; 21:193-6.
22. Pfaar O, Kleine-Tebbe J, Hormann K et al. Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? Immunol Allergy Clin North Am 2011; 31:289-309.
23. Modrzynski M, Mazurek H, Zawisza E. The results of extra diagnostic methods in patients allergic to dust mites treated by specific immunotherapy. Przegl Lek 2005; 62:1337-42.
24. Palma-Carlos AG, Branco-Ferreira M, Santos MC et al. Nasal provocation and immunotherapy. J Investig Allergol Clin Immunol 1999; 9:283-7.
25. Shamji MH, James LK, Durham SR. Serum immunological markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am 2011; 31:311-23.
26. Fujimura T, Yonekura S, Horiguchi S et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol 2011; 139:65-74.